StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.06−0.41 (-1.44%)

Close on Nov 18, 2026Market cap $159.93BP/E 36.9Yield 6.13%

Pfizer operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pfizer's operating cash flow for the twelve months ending Jun 28, 2026 was $13.40B, down 11.8% year over year. For fiscal 2025 it was $11.70B, down 8.2% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $32.58B in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.70B-8.2%
FY2024Dec 31, 2024$12.74B+46.5%
FY2023Dec 31, 2023$8.70B-70.3%
FY2022Dec 31, 2022$29.27B-10.2%
FY2021Dec 31, 2021$32.58B+126.2%
FY2020Dec 31, 2020$14.40B+14.4%
FY2019Dec 31, 2019$12.59B-20.5%
FY2018Dec 31, 2018$15.83B-5.8%
FY2017Dec 31, 2017$16.80B+3.8%
FY2016Dec 31, 2016$16.19B+10.2%
FY2015Dec 31, 2015$14.69B-14.0%
FY2014Dec 31, 2014$17.08B-3.4%
FY2013Dec 31, 2013$17.68B+5.6%
FY2012Dec 31, 2012$16.75B-17.3%
FY2011Dec 31, 2011$20.24B+76.7%
FY2010Dec 31, 2010$11.45B-30.9%
FY2009Dec 31, 2009$16.59B-9.1%
FY2008Dec 31, 2008$18.24B+36.6%
FY2007Dec 31, 2007$13.35B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 28, 2026$835.00M–
Q1 FY2026Mar 29, 2026$2.62B+12.0%
Q4 FY2025Dec 31, 2025$5.35B-20.4%
Q3 FY2025Sep 28, 2025$4.60B-31.4%
Q2 FY2025Jun 29, 2025-$582.00M–
Q1 FY2025Mar 30, 2025$2.34B+114.2%
Q4 FY2024Dec 31, 2024$6.72B+28.3%
Q3 FY2024Sep 29, 2024$6.71B+94.3%
Q2 FY2024Jun 30, 2024-$1.78B–
Q1 FY2024Mar 31, 2024$1.09B-10.1%
Q4 FY2023Dec 31, 2023$5.24B-38.9%
Q3 FY2023Oct 1, 2023$3.46B-42.1%
Q2 FY2023Jul 2, 2023-$1.21B-114.8%
Q1 FY2023Apr 2, 2023$1.21B-81.5%
Q4 FY2022Dec 31, 2022$8.58B+45.1%
Q3 FY2022Oct 2, 2022$5.97B-44.8%
Q2 FY2022Jul 3, 2022$8.17B-27.7%
Q1 FY2022Apr 3, 2022$6.54B+44.1%
Q4 FY2021Dec 31, 2021$5.91B+5.1%
Q3 FY2021Oct 3, 2021$10.83B+418.1%
Q2 FY2021Jul 4, 2021$11.30B+217.8%
Q1 FY2021Apr 4, 2021$4.54B+44.8%
Q4 FY2020Dec 31, 2020$5.63B+49.2%
Q3 FY2020Sep 27, 2020$2.09B-53.7%
Q2 FY2020Jun 28, 2020$3.56B+36.2%
Q1 FY2020Mar 29, 2020$3.13B+84.5%
Q4 FY2019Dec 31, 2019$3.77B-20.5%
Q3 FY2019Sep 29, 2019$4.51B-14.2%
Q2 FY2019Jun 30, 2019$2.61B-32.1%
Q1 FY2019Mar 31, 2019$1.70B-14.4%
Q4 FY2018Dec 31, 2018$4.74B-33.2%
Q3 FY2018Sep 30, 2018$5.26B+7.6%
Q2 FY2018Jul 1, 2018$3.85B+18.7%
Q1 FY2018Apr 1, 2018$1.98B+25.2%
Q4 FY2017Dec 31, 2017$7.09B+17.3%
Q3 FY2017Oct 1, 2017$4.89B+3.2%
Q2 FY2017Jul 2, 2017$3.24B–
Q1 FY2017Apr 2, 2017$1.58B–
Q4 FY2016Dec 31, 2016$6.04B–
Q3 FY2016Oct 2, 2016$4.74B–

More Pfizer figures

See a number that looks wrong?